drugset / Trial / NCT02123966

An Open Label Phase II Trial of Topical Sirolimus for the Treatment of Refractory Oral Chronic Graft-versus-Host-Disease

NCT02123966 ↗

Phase 2 Terminated 10 enrolled Dana-Farber Cancer Institute
NaSingle-groupOpen-labelSupportive care

Summary

This research study is evaluating the effectiveness of topical sirolimus combined with topical steroid therapy, as a possible treatment for oral cGVHD.

Timeline

Start
2014-07
Primary completion
2016-05
Completion
2016-05

Outcome

Outcome not reported

Stopped (Enrollment): “Due to slow accrual, study team has decided to end the study early.”

Drugs

EvaluationDrugModalityDoseRoute
Subject Sirolimus Small molecule 0.1 mg/ml Topical